期刊
PROSTAGLANDINS & OTHER LIPID MEDIATORS
卷 96, 期 1-4, 页码 54-62出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2011.07.005
关键词
MSC; EET-agonist; HO-1; Adipocyte
资金
- NIH [DK068134, HL55601, HL34300]
- The Robert A. Welch Foundation [GM31278]
- The Beatrice Renfield Foundation
Epoxygenase activity and synthesis of epoxyeicosatrienoic acids (EETs) have emerged as important modulators of obesity and diabetes. We examined the effect of the EET-agonist 12-(3-hexylureido)dodec-8(2) enoic acid on mesenchymal stem cell (MSC) derived adipocytes proliferation and differentiation. MSCs expressed substantial levels of EETs and inhibition of soluble epoxide hydrolase (sEH) increased the level of EETs and decreased adipogenesis. EET agonist treatment increased HO-1 expression by inhibiting a negative regulator of HO-1 expression, Bach-1. EET treatment also increased beta catenin and pACC levels while decreasing PPAR gamma C/EBP alpha and fatty acid synthase levels. These changes were manifested by a decrease in the number of large inflammatory adipocytes, TNF alpha. IFN gamma and IL-1 alpha, but an increase in small adipocytes and in adiponectin levels. In summary, EET agonist treatment inhibits adipogenesis and decreases the levels of inflammatory cytokines suggesting the potential action of EETs as intracellular lipid signaling modulators of adipogenesis and adiponectin. (C) 2011 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据